Daily Technical Summary Reports on Biotech Stocks -- Paratek Pharma, Pulmatrix, Verastem, and Biostage
Aug 24, 2017, 06:35 ET
NEW YORK, August 24, 2017 /PRNewswire/ --
If you want a Stock Review on PRTK, PULM, VSTM, or BSTG then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Zacks reported that Biotech stocks specifically fared pretty well during Q2 earnings season, with most of the key players topping earnings and revenue expectations. Quite a few companies raised their outlook for the year as well. In today's premarket research, DailyStockTracker.com draws attention to Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), Pulmatrix Inc. (NASDAQ: PULM), Verastem Inc. (NASDAQ: VSTM), and Biostage Inc. (NASDAQ: BSTG). Register now and get full and free access to these DailyStockTracker.com research reports at:
On Wednesday, shares in Boston, Massachusetts headquartered Paratek Pharmaceuticals Inc. recorded a trading volume of 7.01 million shares, which was above their three months average volume of 612,790 shares. The stock ended at $24.25, skyrocketing 27.30% from the last trading session. The Company's shares have gained 17.72% in the last one month, 16.31% over the previous three months, and 57.47% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.57% and 32.31%, respectively. Furthermore, shares of Paratek Pharma, which focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the US, have a Relative Strength Index (RSI) of 62.41.
On August 22nd, 2017, Paratek Pharma announced that Chief Commercial Officer Adam Woodrow will present at Baird's 2017 Global Healthcare Conference on September 07th, 2017, from 2:00 p.m. to 2:30 p.m. at the InterContinental New York Barclay. Access our complete research report on PRTK for free at:
Lexington, Massachusetts headquartered Pulmatrix Inc.'s stock finished yesterday's session 2.47% higher at $1.74 with a total trading volume of 123,016 shares. The Company's shares have surged 194.92% on an YTD basis. The stock is trading below its 50-day moving average by 20.31%. Furthermore, shares of Pulmatrix, which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology, have an RSI of 39.97.
On August 04th, 2017, Pulmatrix reported its Q2 2017 financial results. For the quarter, net loss was $5.6 million and R&D expenses were $3.4 million. The Company generated no revenues in Q2 2017 compared to $0.3 million for Q2 2016. Additionally, the Company had $11.0 million in cash and cash equivalents as of June 30th, 2017. The complimentary research report on PULM can be downloaded at:
On Wednesday, shares in Needham, Massachusetts headquartered Verastem Inc. jumped 6.93%, ending the day at $3.55. The stock recorded a trading volume of 426,683 shares. The Company's shares have advanced 47.92% in the previous three months and 216.96% since the start of this year. The stock is trading 14.26% and 83.94% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Verastem, which focuses on discovering and developing drugs for the treatment of cancer, have an RSI of 58.76.
On August 08th, 2017, Verastem reported financial results for Q2 ended June 30th, 2017. For Q2 2017, net loss was $13.4 million; R&D expense was $9.0 million; and G&A expense was $4.4 million. As of June 30th, 2017, the Company had cash, cash equivalents, and investments of $57.9 million compared to $80.9 million as of December 31st, 2016. Register for free on DailyStockTracker.com and get access to the latest report on VSTM at:
Holliston, Massachusetts headquartered Biostage Inc.'s shares ended the day 25.24% higher at $0.33. A total volume of 4.81 million shares was traded, which was above their three months average volume of 1.08 million shares. The stock has gained 22.65% over the previous three months. The Company's shares are trading 22.38% below their 50-day moving average. Additionally, shares of Biostage, which engages in developing bioengineered organ implants based on its Cellframe technology, have an RSI of 41.16.
On August 14th, 2017, Biostage announced financial results for the three and six months ended June 30th, 2017. For Q2 2017, net loss was approximately $3.6 million compared to a net loss of approximately $2.7 million for Q2 2016. For the six months ended June 30th, 2017, net loss was approximately $7.4 million compared to a net loss of approximately $5.2 million for the six months ended June 30th, 2016. Download your free research report on BSTG at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Share this article